Qiongding Medical

Qiongding Medical (西安穹顶医疗, Neurodome, Inc.) is a Xi'an-based neurotech company founded in 2019 by a brain-science team from Xi'an Jiaotong University, focused on non-invasive deep-brain neuromodulation built around Temporal Interference (TI) stimulation. Per FreeS Fund's coverage, its TI-based product line spans electrical, ultrasound, and magnetic stimulation, aiming at non-invasive, deep-brain, high-precision, multi-target modulation for central and peripheral nervous system diseases and chronic mental disorders, with clinical progress across multiple indications . FreeS backed it at the angel round and has followed on since: a tens-of-millions-yuan Pre-A in early 2024 , a tens-of-millions-yuan Series A in 2025 co-led by Hofon Capital and iFlytek's venture arm , and, most recently as of April 2026, a near-100-million-yuan Series A+ led by Mingxi Capital with Shunwei, Hofon, iFlytek Ventures, and Oriza Origin continuing to add .